How does Mounjaro (tirzepatide) work for weight loss?
Mounjaro® is an injectable medication that is a combination GIP/GLP-1 receptor agonist. It mimics two hormones our body naturally makes- GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). GLP-1 acts on the pancreas to stimulate the release of insulin which lowers blood sugar and acts on the brain to decrease appetite and cravings. The addition of a GIP agonist to a GLP-1 agonist has been found to promote additional weight loss. Overall, Mounjaro prescriptions can decrease appetite and in combination with a low-calorie nutrition plan and increased physical activity can lead to weight loss. However, it is important to note that currently Mounjaro is only FDA-approved for the treatment of type 2 diabetes and not specifically for weight loss. Zepbound®, which contains the same active ingredient (tirzepatide) as Mounjaro, has been recently approved for the treatment of weight loss. Which medication you are prescribed depends on a variety of factors such as your insurance coverage, any medical conditions you may have, and which medication your healthcare provider determines to be appropriate for you.
Mounjaro® and Zepbound® and their delivery device bases are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.